Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OTC | P00480 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750775 | 0.83 | CASP2 (0.55) | NOD1GRIK1CASP2NAAA | |
| SCHEMBL24696810 | 0.83 | CASP2 (0.55) | NOD1GRIK1CASP2NAAA | |
| SCHEMBL733986 | 0.83 | CASP2 (0.55) | NOD1GRIK1CASP2NAAA | |
| SCHEMBL19302563 | 0.82 | ADRA1A (0.44) | PAOXADRA1ACASP2KDM4EMAPK1 | |
| SCHEMBL13585143 | 0.81 | KDM4E (0.47) | NOD1PAOXADRA1AOTCGRIK1 | |
| SCHEMBL13585140 | 0.81 | KDM4E (0.47) | NOD1PAOXADRA1AOTCGRIK1 | |
| SCHEMBL23253739 | 0.81 | PAOX (0.45) | PAOXADRA1ACASP2KDM4EMAPK1 | |
| SCHEMBL12173943 | 0.80 | SMN1; SMN2 (0.53) | PAOXADRA1ACASP2KDM4EMAPK1 | |
| SCHEMBL17451658 | 0.80 | GSR (0.52) | PAOXOTCGRIK1MEN1KMT2A | |
| SCHEMBL18350239 | 0.80 | OTC (0.58) | NOD1OTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772226-B2 | Methods and compositions for the detection of cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120093724-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093724-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | KLK3, KLK2, KLK5 | NOD1 3174/4885PAOX 3960/4885ADRA1A 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.